Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies

被引：0
|
作者：
Bar, Yael
Dedeoglu, Aylin S.
Fell, Geoffrey G.
Moffett, Natalie J.
Boyraz, Baris
Ly, Amy
Bardia, Aditya
Moy, Beverly
Ellisen, Leif W.
Isakoff, Steven J.
机构：
[1] Massachusetts Gen Hosp, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[4] Harvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1005
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
    Gamrani, Sanaa
    Akhouayri, Laila
    Boukansa, Sara
    Karkouri, Mehdi
    El Fatemi, Hinde
    BREAST JOURNAL, 2023, 2023
  • [42] The Effect of HER2-Low Status on Pathological Complete Response and Survival in Triple-Negative Breast Cancer: A Systemic Review and Meta-Analysis
    Ergun, Yakup
    Akagunduz, Baran
    Karacin, Cengiz
    Turker, Sema
    Ucar, Gokhan
    CLINICAL BREAST CANCER, 2023, 23 (06) : 567 - 575
  • [43] Prognostic value of HER2-low expression according to hormone receptor status in breast cancer patients
    Huszno, J.
    Kolosza, Z.
    Stobiecka, E.
    Ponikiewska, D.
    Szczesniak, B.
    Simek, J.
    Chmielik, E.
    BREAST, 2025, 80
  • [44] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Schnog, John-John B.
    Samson, Michael J.
    Duits, Ashley J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12): : 1143 - 1144
  • [45] Overall survival in breast cancer patients with HER2-low status single- center experience
    Huszno, J.
    Kolosza, Z.
    Stobiecka, E.
    Ponikiewska, D.
    Szczesniak, B.
    Simek, J.
    Chmielik, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1190 - S1190
  • [46] Exploring HER2-low disease: Does it impact breast cancer survival?
    Lopez-Paradis, Assumpcio
    Pous, Anna
    Bernat-Peguera, Adria
    Quiroga, Vanesa
    Cirauqui, Beatriz
    Felip, Eudald
    Bergamino, Milana
    Ferrando-Diez, Angelica
    Romeo, Marga
    Teruel, Iris
    Martinez-Cardus, Anna
    Margeli, Mireia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
    Shohei Shikata
    Takeshi Murata
    Masayuki Yoshida
    Hiromi Hashiguchi
    Yukiko Yoshii
    Ayumi Ogawa
    Chikashi Watase
    Sho Shiino
    Hirokazu Sugino
    Kenjiro Jimbo
    Akiko Maeshima
    Eriko Iwamoto
    Shin Takayama
    Akihiko Suto
    Scientific Reports, 13
  • [48] Biology and Treatment of HER2-Low Breast Cancer
    Nicolo, Eleonora
    Tarantino, Paolo
    Curigliano, Giuseppe
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 117 - 132
  • [49] HER2-Low Breast Cancer: a New Subtype?
    Chiara Corti
    Federica Giugliano
    Eleonora Nicolò
    Paolo Tarantino
    Carmen Criscitiello
    Giuseppe Curigliano
    Current Treatment Options in Oncology, 2023, 24 : 468 - 478
  • [50] Clinical Significance of HER2-low Breast Cancer
    Zaiem, Fadi
    AbuJamea, Asem
    Kheil, Mira
    Numi, Anna
    Abbas, Omar
    Awada, Sanaa
    Almsaddi, Ragad
    Al-Juburi, Saleh
    Larson, Lauren
    Jain, Deepti
    AlSaghir, Maya
    Jang, Hyejeong
    Kim, Seongho
    Bandyopadhyay, Sudeshna
    Jaiman, Sunil
    Ali-Fehmi, Rouba
    CANCER RESEARCH, 2024, 84 (09)
12345